A Study to Obtain Normal Values of Inflammatory Variables From Healthy Subjects

Conditions

Asthma, Copd

Keywords

bronchial, COPD, Asthma, sputum, biopsies

Brief summary

Smoking induces an inflammatory reaction in the airways which can ultimately result in persistent damage and the development of a Chronic Obstructive Pulmonary Disease (COPD). However, not all subjects who smoke end up with COPD. After long-term smoking, approximately 20% of subjects develop COPD. At this time, it is unclear why some subjects develop COPD, whereas others maintain a normal lung function. In addition, smoking has important consequences in asthma. Patients with asthma who smoke have a more severe asthma and more often experience an asthma exacerbation. In addition, it has been shown that inhaled corticosteroids are less effective in smoking asthmatics. With this research project, the researchers will investigate the effects of smoking on the airways. To this end, the researchers will compare markers of airway inflammation, lung function and symptoms between healthy smokers and non-smokers of varying age. In addition, the researchers will compare those healthy subjects with patients with asthma and COPD which are characterized in earlier studies.

Girish B. Nair, Sayf Al‐Katib, Danielle Turner‐Lawrence, Filip Ionescu, Cristóbal Galbán‐Malagón et al. (9 authors)

2021-05-01

10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4467

An assessment of the correlation between robust CT-derived ventilation and pulmonary function test in a cohort with no respiratory symptoms

Girish B. Nair, Craig J. Galbán, Sayf Al‐Katib, Robert H. Podolsky, Maarten van den Berge et al. (7 authors)

British Journal of Radiology2020-12-154 citations

10.1259/bjr.20201218

Identifying a nasal gene expression signature associated with hyperinflation and treatment response in severe COPD.

Faiz A, Imkamp K, van der Wiel E, Boudewijn IM, Koppelman GH, Brandsma CA, Kerstjens HAM, Timens W, Vroegop S, Pasma HR, Boersma WG, Wielders P, van den Elshout F, Mansour K, Steiling K, Spira A, Lenburg ME, Heijink IH, Postma DS, van den Berge M.

2020-10-153 citations

10.1038/s41598-020-72551-0

Nasal gene expression differentiates COPD from controls and overlaps bronchial gene expression.

Boudewijn IM, Faiz A, Steiling K, van der Wiel E, Telenga ED, Hoonhorst SJM, Ten Hacken NHT, Brandsma CA, Kerstjens HAM, Timens W, Heijink IH, Jonker MR, de Bruin HG, Sebastiaan Vroegop J, Pasma HR, Boersma WG, Wielders P, van den Elshout F, Mansour K, Spira A, Lenburg ME, Guryev V, Postma DS, van den Berge M.

2017-12-2137 citations

10.1186/s12931-017-0696-5

Airway wall thickness on HRCT scans decreases with age and increases with smoking.

Telenga ED, Oudkerk M, van Ooijen PM, Vliegenthart R, Ten Hacken NH, Postma DS, van den Berge M.

2017-02-0120 citations

10.1186/s12890-017-0363-0

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* Have not smoked during the last year. * Have never smoked for as long as a year. * Have \< 0.5 packyear.

Exclusion criteria

* Persons who used inhaled or oral corticosteroids during \>5 years, or within the last 5 years. * FEV1 \<1.2 L * A subject is not eligible to enter and participate if he does not agree that we inform his general practicioner about participation in the study and also about any unexpected finding during the study. * Upper respiratory tract infection (e.g. colds), within 2 months. * Pregnancy, or the possibility of being pregnant (i.e. women who do not use adequate anticonception as judged by the investigator). * Malignancy within the past 5 years (except for squamous or basal cell carcinoma of the skin that has been treated with no evidence of recurrence). * Signs or symptoms of any other concomitant disease that, in the eyes of the investigator, can interfere with the study results. * Known recent substance abuse (drug or alcohol). * Claustrophobia.

Design outcomes

Primary

Measure	Time frame
parameters for inflammation and remodelling in airway tissue	The duration of the study is estimated on 2 year

Secondary

Measure	Time frame
Induced sputum, PC20 AMP, spirometrie, questionnaires, CT scan.	2 year

Countries

Netherlands

Outcome results